Skip to main content
Menu
US
US

Resource Center

Filters
Select resource types
Select products & services (1)
Select solutions (1)
Active Filters (2)
Clear All
1 - 12 of 50 Results
Sort by: Best Match
Best Match
Title A-Z
Title Z-A
Filter & Sort
Application Note Icon   Application Note
Detection of human matrix metalloproteinase 9 in complex sample matrices, a comparison of AlphaLISA and colorimetric ELISA immunoassays
This note compares two immunoassay technologies: ELISA (enzyme-linked immunosorbent assay) and AlphaLISA™ (amplified luminescent proximity-based homogeneous assay).
Application Note Icon   Application Note
Developing novel tetraubiquitin substrates and AlphaLISA technology to provide next generation deubiquitinase assays
This application note presents novel biochemical DUB assays that use TUBEs to bind to tetraubiquitin substrates of at least three natural linkages. These assays, combined with Revvity’s AlphaLISA™ technology, allow for the measurement of protein interactions and large protein complexes in a no-wash, homogeneous assay.
Infographic Icon   Infographic
Ditch the wash steps and accelerate discovery
ELISA immunoassays are great, but what if you could improve sensitivity and increase dynamic range all while eliminating wash steps and saving time?
Application Note Icon   Application Note
Tracking inflammasome activity via measuring IL-1β levels with AlphaLISA and HTRF
This application note demonstrates the utility of AlphaLISA™ and HTRF™ for the detection of IL-1β in cell supernatant and serum samples which can be used as a biomarker for inflammasome activity
Application Note Icon   Application Note
Measuring strong to weak binding interactions with AlphaLISA
In this application note, we demonstrate how AlphaLISA can be used to measure three very different types of biomolecular interactions with three very different binding affinities.
Application Note Icon   Application Note
cAMP assay provides flexibility and stable pharmacology
AlphaScreen™ technology provides a quantitative detection of molecules in a homogeneous, no-wash format and can be applied to GPCR research.
Whitepaper Icon   Whitepaper
Exploring current and future approaches for targeting KRAS
Get the latest insights on KRAS and see how it has switched from being an undruggable to a druggable cancer target
Application Note Icon   Application Note
cAMP AlphaScreen assay: a method for the pharmacological characterization and screening of Gαi coupled receptors in whole cells
The note demonstrates the utility of the AlphaScreen-based cAMP Assay kit for the pharmacological characterization and potential high-throughput screening of Gαi-coupled receptors.
Application Note Icon   Application Note
A comparative study of two immunoassay platforms to determine lentivirus titer for CAR-T development
This application note demonstrates a comparative quantification of the p24 titer in a lentiviral GFP control sample using Alliance HIV-1 p24 Antigen ELISA and p24 AlphaLISA immunoassay platforms.
Publication Icon   Literature - Publication Review
Key signaling pathways in liquid cancer: therapeutic targets, screening tools, and future developments
This review highlights some of these signaling pathways and demonstrates how assays based on HTRF and AlphaLISA technologies can be used in the screening and development of new therapies for leukemia and lymphoma treatment.
Application Note Icon   Application Note
LabChip GXII Touch small RNA assay
Improve the productively and cost effectiveness of high-throughput QC screening of small RNA molecules for genomic research and biotherapeutic development.
Guide Icon   Guide
Antibody conjugation to AlphaLISA Acceptor beads detailed protocol
Detailed protocol step-by-step: recommended reagents and materials, antibody assessment and pre-treatment, bead conjugation reaction and bead coupling optimization.
resource-center-page-end-card-bg-illuminator.png
resource-center-page-end-card-bg-illuminator-mobile.png

Looking for technical documents?

Find the technical documents you need, ASAP, in our easy-to-search library.